- Baker Brothers’ 13F portfolio value decreased from $12.33B to $11.54B. The number of positions increased from 121 to 123.
- BioMarin Pharmaceutical Stake was increased during the quarter.
- The top-three positions are Incyte Corporation, Seattle Genetics, and Alexion Pharmaceuticals and they add up to almost ~58% of the portfolio.
This article is part of a series that provides an ongoing
analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly
basis. It is based on Baker Brothers’ regulatory 13F
Form filed on 02/14/2018.
This quarter, Baker Brothers’ 13F portfolio decreased ~6%
from $12.33B to $11.54B. The number of holdings increased from 121 to 123. The
top three holdings are at ~58% while the top five holdings are close to ~71% of
the 13F assets: Incyte Corporation (INCY), Seattle Genetics (SGEN), Alexion
Pharmaceuticals (ALXN), Acadia Pharmaceuticals (ACAD), and BioMarin
Pharmaceuticals (BMRN).
The spreadsheet below highlights changes to Baker Brothers’
13F holdings in Q4 2017. For a look at how the portfolio has progressed, please
see our previous
update:
To learn more about how to profit from a strategy of
following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little
Guy .
No comments :
Post a Comment